Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis.
Guslandi
Mario
M
D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010865:Pilot Projects; D019936:Probiotics / Q000627:therapeutic use*; D012294:Rifamycins / Q000008:administration & dosage / Q000627:therapeutic use*; D000078262:Rifaximin; D012440:Saccharomyces
D000890:Anti-Infective Agents; D012294:Rifamycins; D019804:Mesalamine; D000078262:Rifaximin